Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AFP403
- Development stage
- Unknown
- Lead developer
- NeoMPS
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
AFP403 is an **alpha-fetoprotein–derived peptide** containing a human leukocyte antigen (HLA)-A24–restricted cytotoxic T lymphocyte epitope from tumor antigens expressed in hepatocellular carcinoma (HCC). It is designed to stimulate cytotoxic T-cell responses against HCC cells. Preclinical and clinical studies, including phase I safety and efficacy trials, demonstrated that AFP403, combined with AFP357, was safe and induced tumor control in a subset of patients. AFP403 is administered subcutaneously as part of immunotherapy protocols targeting HCC, especially in patients with HLA-A24 alleles[1].
- Other names
- AFP 403-411AFP403-411AFP-403-411alpha-fetoprotein-derived peptide 403
02
Targets
AFP (Alpha-fetoprotein)T-cell receptor restricted by HLA-A*24:02HLA-A*24 (Major histocompatibility complex class I molecule presenting MAGE-A4 peptide)
Beyond the preview
Go deeper on AFP403.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AFP403.